IMPACT OF MULTIPLE GENE MUTATIONS IN DETERMINING THE SEVERITY OF CARDIOMYOPATHY AND HEART FAILURE

被引:32
|
作者
Tsoutsman, Tatiana [1 ,2 ]
Bagnall, Richard D. [1 ]
Semsarian, Christopher [1 ,2 ,3 ]
机构
[1] Centenary Inst, Agnes Ginges Ctr Mol Cardiol, Sydney, NSW, Australia
[2] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia
[3] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
关键词
death; genes; heart failure; hypertrophic cardiomyopathy; multiple mutations;
D O I
10.1111/j.1440-1681.2008.05037.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Familial hypertrophic cardiomyopathy (FHC) is a primary cardiac disorder characterized by myocardial hypertrophy that demonstrates substantial diversity in both genetic causes and clinical manifestations. 2. Clinical heterogeneity can be explained by the causative gene (at least 13 have been identified to date), the position of the amino acid residue affected by a mutation within the protein (over 450 mutations have been reported to date) and modifying genetic and environmental factors. 3. Multiple mutations are found in up to 5% of human FHC cases, who typically present with a more severe phenotype compared with single-mutation carriers (i.e. earlier onset of disease, greater left ventricular hypertrophy and a higher incidence of sudden cardiac death events). 4. Multiple mutations usually involve MYH7, MYBPC3 and, to a lesser extent, TNNI2, reflecting the higher contribution of mutations in these genes to FHC. 5. Multiple-mutation mouse models appear to mimic the human multiple-mutation phenotype and, thus, will help improve our understanding of disease pathogenesis. The models provide a tool for future studies of disease mechanisms and signalling pathways in FHC and its sequelae (i.e. heart failure and sudden death), thereby allowing identification of novel targets for potential therapies and disease prevention strategies.
引用
收藏
页码:1349 / 1357
页数:9
相关论文
共 50 条
  • [41] Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease
    Lucrecia Marcano, Ana
    Marisol Lugo, Leslie
    Besteiro, Adrian
    Gomez-Lara, Josep
    Roura, Gerard
    Fuentes, Lara
    Gracida, Montserrat
    Teruel, Luis
    Romaguera, Rafael
    Gabriela Sosa, Silvia
    Cequier, Angel
    Gomez-Hospital, Joan A.
    Comin-Colet, Josep
    Luis Ferreiro, Jose
    THROMBOSIS RESEARCH, 2020, 196 : 215 - 221
  • [42] Coexistence of mitochondrial DNA and β myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure
    Arbustini, E
    Fasani, R
    Morbini, P
    Diegoli, M
    Grasso, M
    Dal Bello, B
    Marangoni, E
    Banfi, P
    Banchieri, N
    Bellini, O
    Comi, G
    Narula, J
    Campana, C
    Gavazzi, A
    Danesino, C
    Viganó, M
    HEART, 1998, 80 (06) : 548 - 558
  • [43] Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy
    Kaski, Juan Pablo
    Syrris, Petros
    Esteban, Maria Teresa Tome
    Jenkins, Sharon
    Pantazis, Antonios
    Deanfield, John E.
    McKenna, William J.
    Elliott, Perry M.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2009, 2 (05) : 436 - 441
  • [44] Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy
    Yubao Zou
    Jizheng Wang
    Xuan Liu
    Yilu Wang
    Yi Chen
    Kai Sun
    Shuo Gao
    Channa Zhang
    Zhimin Wang
    Yin Zhang
    Xinxing Feng
    Ying Song
    Yajie Wu
    Hongju Zhang
    Lei Jia
    Hu Wang
    Dong Wang
    Chaowu Yan
    Minjie Lu
    Xianliang Zhou
    Lei Song
    Rutai Hui
    Molecular Biology Reports, 2013, 40 : 3969 - 3976
  • [45] Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy
    Zou, Yubao
    Wang, Jizheng
    Liu, Xuan
    Wang, Yilu
    Chen, Yi
    Sun, Kai
    Gao, Shuo
    Zhang, Channa
    Wang, Zhimin
    Zhang, Yin
    Feng, Xinxing
    Song, Ying
    Wu, Yajie
    Zhang, Hongju
    Jia, Lei
    Wang, Hu
    Wang, Dong
    Yan, Chaowu
    Lu, Minjie
    Zhou, Xianliang
    Song, Lei
    Hui, Rutai
    MOLECULAR BIOLOGY REPORTS, 2013, 40 (06) : 3969 - 3976
  • [46] Impact of right ventricular pacing on patients with Chagas cardiomyopathy with chronic systolic heart failure
    Parra, Andrelisa V.
    Bestetti, Reinaldo B.
    Cardinalli-Neto, Augusto
    Otaviano, Ana Paula
    Nogueira, Paulo R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 154 (02) : 219 - 220
  • [47] How to assess the severity of heart failure?
    Kabra, Nitin
    Cooper, Howard A.
    Naidu, Srihari S.
    CURRENT OPINION IN CRITICAL CARE, 2020, 26 (04) : 386 - 391
  • [48] The impact of chronic heart failure on misinterpretation and misclassification of chronic obstructive pulmonary disease severity
    Vyshnyvetskyy, I. I.
    Borovtsova, A. Yu.
    ZAPOROZHYE MEDICAL JOURNAL, 2016, (02) : 27 - 30
  • [49] Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies
    Mazur, Matylda
    Braksator, Wojciech
    Popjes, Eric
    CURRENT CARDIOLOGY REPORTS, 2024, 26 (09) : 985 - 994
  • [50] New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies
    G. A. MacGowan
    D. M. McNamara
    Irish Journal of Medical Science, 2002, 171 : 99 - 104